F 4614

a mutein of tumor necrosis factor alpha (TNF-alpha); contains mutations of Thr(5) substituted by Gly, Pro(6) substituted by Asp, and Arg(29) substituted by Val; the mutations resulted in cell-adhesive Arg-Gly-Asp and reduced hypotensive effects and lower lethality

Also Known As:

F-4614; F4614

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Carbohydrates: 22023
- Glycoconjugates: 1353
  - Glycoproteins: 24834
    - Tumor Necrosis Factor-alpha: 62515
      - F 4614: 3
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
- Peptides: 82426
  - Intercellular Signaling Peptides and Proteins: 29768
    - Cytokines: 164289
      - Monokines: 214
        Tumor Necrosis Factor-alpha: 62515
        F 4614: 3
      - Tumor Necrosis Factors: 152
        Tumor Necrosis Factor-alpha: 62515
        F 4614: 3
Biological Factors: 2472
- Intercellular Signaling Peptides and Proteins: 29768
  - Cytokines: 164289
    - Monokines: 214
      - Tumor Necrosis Factor-alpha: 62515
        F 4614: 3
    - Tumor Necrosis Factors: 152
      - Tumor Necrosis Factor-alpha: 62515
        F 4614: 3

Experts

1.	Fujita, F: 1 article (10/2000)
2.	Fujita, M: 1 article (10/2000)
3.	Kawagoe, T: 1 article (10/2000)
4.	Koike, M: 1 article (10/2000)
5.	Kuroda, K: 1 article (10/2000)
6.	Mayumi, T: 1 article (10/2000)
7.	Mitsuishi, Y: 1 article (10/2000)
8.	Miyata, K: 1 article (10/2000)
9.	Nakagawa, S: 1 article (10/2000)
10.	Nomura, M: 1 article (10/2000)

Related Diseases

1.	Neoplasms (Cancer) 07/01/1998 - "Immunohistochemical analysis of the tumors treated by F4614 revealed that tumors were surrounded with a large number of Mac-1+ cells and a small number of CD4+ and CD8+ T cells; that suggests that intratumoral injection of F4614 elicited host immunoreactions. " 07/01/1998 - "F4614 significantly inhibited growth of all four tumor cells in vitro. " 08/01/1995 - "These results indicated that F4614 has several advantages as a systemic therapeutic drug in the treatment of cancer." 07/01/1998 - "Our study investigated the anti-tumor effects of F4614 against hepatoma cells in vitro and in vivo. " 10/16/2000 - "Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice."
2.	Hepatocellular Carcinoma (Hepatoma) 07/01/1998 - "Our study investigated the anti-tumor effects of F4614 against hepatoma cells in vitro and in vivo. " 07/01/1998 - "A murine hepatoma cell line, MH134, when incubated in the presence of F4614, exhibited upregulation of surface major histocompatibility complex (MHC) class-I, intercellular adhesion molecule-1 (ICAM-1) and B7-1 molecules, and a decreased proportion of cells in the G2/M phase of the cell cycle. " 07/01/1998 - "A novel human tumor necrosis factor alfa mutein, F4614, inhibits in vitro and in vivo growth of murine and human hepatoma: implication for immunotherapy of human hepatocellular carcinoma."
3.	Sarcoma (Soft Tissue Sarcoma) 07/01/1998 - "F4614 is known to lack hypotensive effects of human TNF-alpha without losing its anti-tumor effect in mice transplanted with Meth-A sarcoma. "
4.	Fibrosarcoma 08/01/1995 - "In addition, the therapeutically effective dose of F4614 to MethA fibrosarcoma-transplanted mice was increased compared with that of TNF-alpha, indicating a wide therapeutic index. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)

Related Therapies and Procedures

1.	Immunotherapy